5D2D
Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768
5D2D の概要
| エントリーDOI | 10.2210/pdb5d2d/pdb |
| 関連するBIRD辞書のPRD_ID | PRD_900003 |
| 分子名称 | 14-3-3 protein zeta/delta, Cystic fibrosis transmembrane conductance regulator, beta-D-fructofuranose-(2-1)-alpha-D-glucopyranose, ... (5 entities in total) |
| 機能のキーワード | protein-peptide complex, phosphorylation, tandem binding, peptide binding protein |
| 由来する生物種 | Homo sapiens (Human) 詳細 |
| タンパク質・核酸の鎖数 | 3 |
| 化学式量合計 | 56716.59 |
| 構造登録者 | |
| 主引用文献 | Stevers, L.M.,Lam, C.V.,Leysen, S.F.,Meijer, F.A.,van Scheppingen, D.S.,de Vries, R.M.,Carlile, G.W.,Milroy, L.G.,Thomas, D.Y.,Brunsveld, L.,Ottmann, C. Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3 and the R domain of CFTR. Proc.Natl.Acad.Sci.USA, 113:E1152-E1161, 2016 Cited by PubMed Abstract: Cystic fibrosis is a fatal genetic disease, most frequently caused by the retention of the CFTR (cystic fibrosis transmembrane conductance regulator) mutant protein in the endoplasmic reticulum (ER). The binding of the 14-3-3 protein to the CFTR regulatory (R) domain has been found to enhance CFTR trafficking to the plasma membrane. To define the mechanism of action of this protein-protein interaction, we have examined the interaction in vitro. The disordered multiphosphorylated R domain contains nine different 14-3-3 binding motifs. Furthermore, the 14-3-3 protein forms a dimer containing two amphipathic grooves that can potentially bind these phosphorylated motifs. This results in a number of possible binding mechanisms between these two proteins. Using multiple biochemical assays and crystal structures, we show that the interaction between them is governed by two binding sites: The key binding site of CFTR (pS768) occupies one groove of the 14-3-3 dimer, and a weaker, secondary binding site occupies the other binding groove. We show that fusicoccin-A, a natural-product tool compound used in studies of 14-3-3 biology, can stabilize the interaction between 14-3-3 and CFTR by selectively interacting with a secondary binding motif of CFTR (pS753). The stabilization of this interaction stimulates the trafficking of mutant CFTR to the plasma membrane. This definition of the druggability of the 14-3-3-CFTR interface might offer an approach for cystic fibrosis therapeutics. PubMed: 26888287DOI: 10.1073/pnas.1516631113 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.1 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






